Point of NO return for nitrergic nerves in diabetes: A new insight into diabetic complications

Current Pharmaceutical Design

Volumn 10, Issue 29, 2004, Pages 3683-3695

  Cellek, S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Advanced glycation endproducts; Autonomic; Axonal transport; Diabetes mellitus; Diabetic complications; Erectile dysfunction; Nitrergic; Nitric oxide

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA TOCOPHEROL; AMINOGUANIDINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GUANYLATE CYCLASE ACTIVATOR; INSULIN; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PROTEIN KINASE C INHIBITOR; PROTEIN KINASE INHIBITOR; PYRIDOXAMINE; REACTIVE OXYGEN METABOLITE; RHO KINASE; THIAZOLE DERIVATIVE;

APOPTOSIS; AUTONOMIC NERVE; AUTONOMIC NERVOUS SYSTEM; AUTONOMIC NEUROPATHY; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE COURSE; DRUG TARGETING; ERECTILE DYSFUNCTION; EXPERIMENTAL MODEL; HUMAN; NERVE DEGENERATION; NERVE FIBER; NERVE FIBER TRANSPORT; NEUROTRANSMISSION; NITRERGIC NERVE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STEM CELL TRANSPLANTATION;

ANIMALS; APOPTOSIS; DIABETIC NEUROPATHIES; HUMANS; HYPOGLYCEMIC AGENTS; NERVE DEGENERATION; NEUROTRANSMITTER AGENTS; NITRERGIC NEURONS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE I;

EID: 6344294371     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043382792     Document Type: Review

References (246)

1. Bredt DS. Endogenous nitric oxide synthesis: biological functions and pathophysiology. Free Radic Res 1999; 31: 577-596.
2. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-142.
3. Moncada S, Higgs A, Furchgott R. International Union of Pharmacology Nomenclature in Nitric Oxide Research. Pharmacol Rev 1997; 49: 137-142.
4. Rand MJ. Nitrergic transmission: nitric oxide as a mediator of non-adrenergic, non-cholinergic neuro-effector transmission. Clin Exp Pharmacol Physiol 1992; 19: 147-169.
5. Cellek S. Nitrergic-noradrenergic interaction in penile erection: A new insight into erectile dysfunction. Drugs Today (Barc) 2000; 36: 135-146.
6. Wiklund NP, et al. Visualisation of nitric oxide released by nerve stimulation. J Neurosci Res 1997; 47: 224-232.
7. Vincent SR. In: Toda N, Moncada S, Furchgott R, Higgs A Ed, Nitric Oxide in the Peripheral Nervous System. London, Portland Press 2000; 1-16.
8. Cellek S, Moncada S. Nitrergic control of peripheral sympathetic responses in the human corpus cavernosum: a comparison with other species. Proc Natl Acad Sci USA 1997; 94: 8226-8231.
9. Cellek S, Moncada S. Nitrergic modulation of cholinergic responses in the opossum lower oesophageal sphincter. Br J Pharmacol 1997; 122: 1043-1046.
10. Bredt DS, Hwang PM, Snyder SH. Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature 1990; 347: 768-770.
11. Toda N, Okamura T. The pharmacology of nitric oxide in the peripheral nervous system of blood vessels. Pharmacol Rev 2003; 55: 271-324.
12. Blottner D, Grozdanovic Z, Gossrau R. Histochemistry of nitric oxide synthase in the nervous system. Histochem J 1995; 27: 785-811.
13. Blottner D, Baumgarten HG. Nitric oxide synthetase (NOS)-containing sympathoadrenal cholinergic neurons of the rat IML-cell column: evidence from histochemistry, immunohistochemistry, and retrograde labeling. J Comp Neurol 1992; 316: 45-55.
14. Ceccatelli S, Lundberg JM, Zhang X, Aman K, Hokfelt T. Immunohistochemical demonstration of nitric oxide synthase in the peripheral autonomic nervous system. Brain Res 1994; 656: 381-395.
15. Saito S, et al. Rat spinal cord neurons contain nitric oxide synthase. Neuroscience 1994; 59: 447-456.
16. Klimaschewski L. et al. Nitric oxide synthase in cardiac nerve fibers and neurons of rat and guinea pig heart. Circ Res 1992; 71: 1533-1537.
17. Sosunov AA, Hassall CJ, Loesch A, Turmaine M, Burnstock G. Nitric oxide synthase-containing neurotics and nerve fibres within cardiac ganglia of rat and guinea-pig: an electron-microscopic immunocytochemical study. Cell Tissue Res 1996; 284: 19-28.
18. Sosunov AA, Hassall CJ, Loesch A, Turmaine M, Burnstock G. Ultrastructural investigation of nitric oxide synthase-immunoreactive nerves associated with coronary blood vessels of rat and guinea-pig. Cell Tissue Res 1995; 280: 575-582.
19. Tanaka K, Ohshima H, Esumi H, Chiba T. Direct synaptic contacts of nitric oxide synthase-immunoreactive nerve terminals on the neurons of the intracardiac ganglia ofthe guinea pig. Neurosci Lett 1993; 158: 67-70.
20. Horackova M, Armour JA, Hopkins DA, Huang MH. Nitric oxide modulates signaling between cultured adult peripheral cardiac neurons and cardiomyocytes. Am J Physioi 1995; 269: C504-C510.
21. Jew JY, Fink CA, Williams TH. Tyrosine hydroxylase- and nitric oxide synthase-immunoreactive nerve fibers in mitral valve of young adult and aged Fischer 344 rats. J Auton Nerv Syst 1996; 58: 35-43.
22. Gillespie JS, Liu XR, Martin W. The effects of L-arginine and NG-monomethyl L-arginine on the response of the rat anococcygeus muscle to NANC nerve stimulation. Br J Pharmacol 1989; 98: 1080-1082.
23. Moncada S. Nitric oxide in the vasculature: physiology and pathophysiology. Ann N Y Acad Sci 1997; 811: 60-67.
24. Sander M, Hansen J, Victor RG. The sympathetic nervous system is involved in the maintenance but not initiation of the hypertension induced by N(omega)-nitro-L-arginine methyl ester. Hypertension 1997; 30: 64-70.
25. Sander M, Hansen PG, Victor RG. Sympathetically mediated hypertension caused by chronic inhibition of nitric oxide. Hypertension 1995; 26: 691-695.
26. Sander M, Victor RG. Neural mechanisms in nitric-oxide-deficient hypertension. Curr Opin Nephrol Hypertens 1999; 8: 61-73.
27. Toda N, Kitamura Y, Okamura T. Neural mechanism of hypertension by nitric oxide synthase inhibitor in dogs. Hypertension 1993; 21: 3-8.
28. Moore PK, Handy RL. Selective inhibitors of neuronal nitric oxide synthase - is no NOS really good NOS for the nervous system? Trends Pharmacol Sci 1997; 18: 204-211.
29. Huang PL, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995; 377: 239-242.
30. Nelson RJ, et al. Behavioural abnormalities in male mice lacking neuronal nitric oxide synthase. Nature 1995; 378: 383-386.
31. Huang PL, Dawson TM, Bredt DS, Snyder SH, Fishman MC. Targeted disruption of the neuronal nitric oxide synthase gene. Cell 1993; 75: 1273-1286.
32. Gonzalez-Cadavid NF, et al. Expression of penile neuronal nitric oxide synthase variants in the rat and mouse penile nerves. Biol Reprod 2000; 63: 704-714.
33. Bult H, et al. Nitric oxide as an inhibitory non-adrenergic non-cholinergic neurotransmitter. Nature 1990; 345: 346-347.
34. Boeckxstaens GE, et al. Clinical relevance of nitric oxide in the gut. Lancet 1994; 344: 129-
35. Boeckxstaens GE, Pelckmans PA, Herman AG, Van Maercke YM. Involvement of nitric oxide in the inhibitory innervation of the human isolated colon. Gastroenterology 1993; 104: 690-697.
36. Rolle U, Nemeth L, Puri P. Nitrergic innervation of the normal gut and in motility disorders of childhood. J Pediatr Surg 2002; 37: 551-567.
37. Wester T, O'Briain DS, Puri P. Notable postnatal alterations in the myenteric plexus of normal human bowel. Gut 1999; 44: 666-674.
38. Huang PL, Dawson TM, Bredt DS, Snyder SH, Fishman MC. Targeted disruption of the neuronal nitric oxide synthase gene. Cell 1993; 75: 1273-1286.
39. Rolle U, Chertin B, Nemeth L, Puri P. Demonstration of nitrergic and cholinergic innervation in whole-mount preparations of rabbit, pig, and human upper urinary tract. Pediatr Surg Int 2002; 18: 315-318.
40. de Groat WC, et al. Neural control of the urethra. Scand J Urol Nephrol Suppl 2001; 35-43.
41. de Groat WC, Yoshimura N. Pharmacology of the lower urinary tract. Annu Rev Pharmacol Toxicol 2001; 41: 691-721.
42. Burnett AL, Calvin DC, Silver RI, Peppas DS, Docimo SG. Immunohistochemical description of nitric oxide synthase isoforms in human clitoris. J Urol 1997; 158: 75-78.
43. Hedlund P, Alm P, Andersson KE. NO synthase in cholinergic nerves and NO-induced relaxation in the rat isolated corpus cavernosum. Br J Pharmacol 1999; 127: 349-360.
44. Cellek S, Moncada S. In: Toda N, Moncada S, Furchgott R, Higgs A Ed, Nitric oxide and the peripheral nervous system. London, Portland Press. 2000; 61-76.
45. Mizusawa H, Hedlund P, Hakansson A, Alm P, Andersson KE. Morphological and functional in vitro and in vivo characterization of the mouse corpus cavernosum. Br J Pharmacol 2001; 132: 1333-1341.
46. Creighton SM, Crouch NS, Foxwell NA, Cellek S. Functional evidence for nitregic neurotransmission in a humna clitoral corpus cavernosum: a case study. Int J Impot Res 2004; 16: 319-324.
47. Andersson KE. Erectile physiological and pathophysiological pathways involved in erectile dysfunction. J Urol 2003; 170: S6-13.
48. Azadzoi KM, et al. Endothelium-derived nitric oxide and cyclooxygenase products modulate corpus cavernosum smooth muscle tone. J Urol 1992; 147: 220-225.
49. Saenz de Tejada I, et al. Cholinergic neurotransmission in human corpus cavernosum. I. Responses of isolated tissue. Am J Physiol 1988; 254: H459-H467.
50. Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snyder SH. Nitric oxide: a physiologic mediator of penile erection. Science 1992; 257: 401-403.
51. Brindley GS. Pilot experiments on the actions of drugs injected into the human corpus cavernosum penis. Br J Pharmacol 1986; 87: 495-500.
52. Okamura T, et al. Effects of endothelial impairment by saponin on the responses to vasodilators and nitrergic nerve stimulation in isolated canine corpus cavernosum. Br J Pharmacol 1999; 127: 802-808.
53. Hurt KJ, et al. Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection. Proc Natl Acad Sci USA 2002; 99: 4061-4066.
54. Jaffrey SR, Snyder SH. PIN: an associated protein inhibitor of neuronal nitric oxide synthase. Science 1996; 274: 774-777.
55. Vernet D, Bonavera JJ, Swerdloff RS, Gonzalez-Cadavid NF, Wang C. Spontaneous expression of inducible nitric oxide synthase in the hypothalamus and other brain regions of aging rats. Endocrinology 1998; 139: 3254-3261.
56. Jaffrey SR, Snowman AM, Eliasson MJ, Cohen NA, Snyder SH. CAPON: a protein associated with neuronal nitric oxide synthase that regulates its interactions with PSD95. Neuron 1998; 20: 115-124.
57. Magee TR, et al. Protein inhibitor of nitric oxide synthase (NOS) and the N-methyl-D-aspartate receptor are expressed in the rat and mouse penile nerves and colocalize with penile neuronal NOS. Biol Reprod 2003; 68: 478-488.
58. Gonzalez-Cadavid NF, Ryndin I, Vernet D, Magee TR, Rajfer J. Presence of NMDA receptor subunits in the male lower urogenital tract. J Androl 2000; 21: 566-578.
59. Burnett AL, et al. Nitric oxide-dependent penile erection in mice lacking neuronal nitric oxide synthase. Mol Med 1996; 2: 288-296.
60. Magee TR, et al. Gene therapy of erectile dysfunction in the rat with penile neuronal nitric oxide synthase. Biol Reprod 2002; 67: 1033-1041.
61. Penson DF, Ng C, Cai L, Rajfer J, Gonzalez-Cadavid NF. Androgen and pituitary control of penile nitric oxide synthase and erectile function in the rat. Biol Reprod 1996; 55: 567-574.
62. Reilly CM, Zamorano P, Stopper VS, Mills TM. Androgenic regulation of NO availability in rat penile erection. J Androl 1997; 18: 110-115.
63. Marin R, Escrig A, Abreu P, Mas M. Androgen-dependent nitric oxide release in rat penis correlates with levels of constitutive nitric oxide synthase isoenzymes. Biol Reprod 1999; 61: 1012-1016.
64. Park KH, Kim SW, Kim KD, Paick JS. Effects of androgens on the expression of nitric oxide synthase mRNAs in rat corpus cavernosum. BJU Int 1999; 83: 327-333.
65. Keilbach A, Ruth P, Hofmann F. Detection of cGMP dependent protein kinase isozymes by specific antibodies. Eur J Biochem 1992; 208: 467-473.
66. Lohmann SM, Vaandrager AB, Smolenski A, Walter U, De Jonge HR. Distinct and specific functions of cGMP-dependent protein kinases. Trends Biochem Sci 1997; 22: 307-312.
67. Hedlund P, et al. Erectile dysfunction in cyclic GMP-dependent kinase 1-deficient mice. Proc Natl Acad Sci USA 2000; 97: 2349-2354.
68. Ewing DJ, Clarke BF. Diabetic autonomic neuropathy: present insights and future prospects. Diabetes Care 1986; 9: 648-665.
69. Ziegler D, Gries FA, Spuler M, Lessmann F. The epidemiology of diabetic neuropathy. Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study Group. J Diabetes Complications 1992; 6: 49-57.
70. Faerman I, Glocer L, Fox D, Jadzinsky MN, Rapaport M. Impotence and diabetes. Histological studies of the autonomic nervous fibers of the corpora cavernosa in impotent diabetic males. Diabetes 1974; 23: 971-976.
71. Stewart IM, Hosking DJ, Preston BJ, Atkinson M. Oesophageal motor changes in diabetes mellitus. Thorax 1976; 31: 278-283.
72. Faerman I, et al. Autonomic neuropathy and painless myocardial infarction in diabetic patients. Histologic evidence of their relationship. Diabetes 1977; 26: 1147-1158.
73. Schmidt RE, Scharp DW. Axonal dystrophy in experimental diabetic autonomic neuropathy. Diabetes 1982; 31: 761-770.
74. Wilson HF, Mayer JH, Clarke SA, Tomlinson DR. An examination of autonomic nervous function in genetically diabetic mice. J Auton Pharmacol 1982; 2: 147-153.
75. Tomlinson DR, Yusof AP. Autonomic neuropathy in the alloxan-diabetic rat. J Auton Pharmacol 1983; 3: 257-263.
76. Schmidt RE, Plurad SB. Ultrastructural and biochemical characterization of autonomic neuropathy in rats with chronic streptozotocin diabetes. J Neuropathol Exp Neurol 1986; 45: 525-544.
77. Moss HE, Crowe R, Burnstock G. The seminal vesicle in eight and 16 week streptozotocin-induced diabetic rats: adrenergic, cholinergic and peptidergic innervation. J Urol 1987; 138: 1273-1278.
78. Anderson LC, Garrett JR, Thulin A, Proctor GB. Effects of streptozocin-induced diabetes on sympathetic and parasympathetic stimulation of parotid salivary gland function in rats. Diabetes 1989; 38: 1381-1389.
79. Loesch A, Belai A, Lincoln J, Burnstock G. Enteric nerves in diabetic rats: electron microscopic evidence for neuropathy of vasoactive intestinal polypeptide-containing fibres. Acta Neuropathol (Berl) 1986; 70: 161-168.
80. Belai A, Lincoln J, Milner P, Burnstock G. Progressive changes in adrenergic, serotonergic, and peptidergic nerves in proximal colon of streptozotocin-diabetic rats. Gastroenterology 1988; 95: 1234-1241.
81. Schmidt RE, et al. Ultrastructural and immunohistochemical characterization of autonomic neuropathy in genetically diabetic Chinese hamsters. Lab Invest 1989; 61: 77-92.
82. Belai A, Lincoln J, Milner P, Burnstock G. Differential effect of streptozotocin-induced diabetes on the innervation of the ileum and distal colon. Gastroenterology 1991; 100: 1024-1032.
83. Yagihashi S, Sima AA. Diabetic autonomic neuropathy in BB rat. Ultrastructural and morphometric changes in parasympathetic nerves. Diabetes 1986; 35: 733-743.
84. Okada S, et al. Relationship between cardiac autonomic neuropathy and diabetic microangiopathies and macroangiopathy in patients with non-insulin-dependent diabetes mellitus. J Int Med Res 1996; 24: 92-98.
85. Willenheimer RB, et al. Parasympathetic neuropathy associated with left ventricular diastolic dysfunction in patients with insulin-dependent diabetes mellitus. Scand Cardiovasc J 1998; 32: 17-22.
86. Schmidt RE. Neuronal preservation in the sympathetic ganglia of rats with chronic streptozotocin-induced diabetes. Brain Res 2001; 921: 256-259.
87. Schmidt RE. Neuropathology and pathogenesis of diabetic autonomic neuropathy. Int Rev Neurobiol 2002; 50: 257-292.
88. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003; 26: 1553-1579.
89. Pfeifer MA, Schumer MP. Cardiovascular autonomic neuropathy. Where have we been and where are we going? Diabetes Care 1994; 17: 1545-1546.
90. Cohen JA, Estacio RO, Lundgren RA, Esler AL, Schrier RW. Diabetic autonomic neuropathy is associated with an increased incidence of strokes. Auton Neurosci 2003; 108: 73-78.
91. Morita Y, Hardebo JE, Bouskela E. The role of nitric oxide in the cerebrovascular flow response to stimulation of postganglionic parasympathetic nerves in the rat. J Auton Nerv Syst 1994; 49 Suppl: S77-S81.
92. Stevens MJ, et al. Cardiac sympathetic dysinnervation in diabetes: implications for enhanced cardiovascular risk. Circulation 1998; 98: 961-968.
93. Wald MR, Borda ES, Sterin-Borda L. Participation of nitric oxide and cyclic GMP in the supersensitivity of acute diabetic rat myocardium by cholinergic stimuli. Biochem Pharmacol 1998; 55: 1991-1999.
94. Joffe H, et al. Abnormal cardiac function in the streptozotocin-induced non-insulin-dependent diabetic rat: noninvasive assessment with doppler echocardiography and contribution of the nitric oxide pathway. J Am Coll Cardiol 1999; 34: 2111-2119.
95. Martinez-Nieves B, Collins HL, Dicarlo SE. Autonomic and endothelial dysfunction in experimental diabetes. Clin Exp Hypertens 2000; 22: 623-634.
96. D'Amico M, et al. High glucose induces ventricular instability and increases vasomotor tone in rats. Diabetologia 2001; 44: 464-470.
97. Koch KL. Diabetic gastropathy: gastric neuromuscular dysfunction in diabetes mellitus: a review of symptoms, pathophysiology, and treatment. Dig Dis Sci 1999; 44: 1061-1075.
98. Jenkinson KM, Reid JJ. Effect of diabetes on relaxations to non-adrenergic, non-cholinergic nerve stimulation in longitudinal muscle of the rat gastric fundus. Br J Pharmacol 1995; 116: 1551-1556.
99. Martinez-Cuesta MA, Massuda H, Whittle BJ, Moncada S. Impairment of nitrergic-mediated relaxation of rat isolated duodenum by experimental diabetes. Br J Pharmacol 1995; 114: 919-924.
100. Takahashi T, Nakamura K, Itoh H, Sima AA, Owyang C. Impaired expression of nitric oxide synthase in the gastric myenteric plexus of spontaneously diabetic rats. Gastroenterology 1997; 113: 1535-1544.
101. Wrzos HE, Cruz A, Polavarapu R, Shearer D, Ouyang A. Nitric oxide synthase (NOS) expression in the myenteric plexus of streptozotocin-diabetic rats. Dig Dis Sci 1997; 42: 2106-2110.
102. Spangeus A, Suhr O, El Salhy M. Diabetic state affects the innervation of gut in an animal model of human type 1 diabetes. Histol Histopathol 2000; 15: 739-744.
103. He CL, et al. Loss of interstitial cells of cajal and inhibitory innervation in insulin-dependent diabetes. Gastroenterology 2001; 121: 427-434.
104. Spangeus A, El Salhy M. Myenteric plexus of obese diabetic mice (an animal model of human type 2 diabetes). Histol Histopathol 2001; 16: 159-165.
105. Yoneda S, Kadowaki M, Kuramoto H, Fukui H, Takaki M. Enhanced colonic peristalsis by impairment of nitrergic enteric neurons in spontaneously diabetic rats. Auton Neurosci 2001; 92: 65-71.
106. Gibson TM, Cotter MA, Cameron NE. Effects of alpha-lipoic acid on impaired gastric fundus innervation in diabetic rats. Free Radic Biol Med 2003; 35: 160-168.
107. Mearin F, Camilleri M, Malagelada JR. Pyloric dysfunction in diabetics with recurrent nausea and vomiting. Gastroenterology 1986; 90: 1919-1925.
108. Watkins CC, et al. Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy. J Clin Invest 2000; 106: 373-384.
109. Ellenberg M. Development of urinary bladder dysfunction in diabetes mellitus. Ann Intern Med 1980; 92: 321-323.
110. Andersson KE, Persson K. Nitric oxide synthase and the lower urinary tract: possible implications for physiology and pathophysiology. Scand J Urol Nephrol Suppl 1995; 175: 43-53.
111. Mumtaz FH, et al. Alterations in the nitric oxide synthase binding sites and non-adrenergic, non-cholinergic mediated smooth muscle relaxation in the diabetic rabbit bladder outlet: possible relevance to the pathogenesis of diabetic cystopathy. J Urol 1999; 162: 558-566.
112. Burnett AL, et al. Urinary bladder-urethral sphincter dysfunction in mice with targeted disruption of neuronal nitric oxide synthase models idiopathic voiding disorders in humans. Nat Med 1997; 3: 571-574.
113. McCulloch DK, Campbell IW, Wu FC, Prescott RJ, Clarke BF. The prevalence of diabetic impotence. Diabetologia 1980; 18: 279-283.
114. Bacon CG, et al. Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care 2002; 25: 1458-1463.
115. Enzlin P, Mathieu C, Van Den BA, Vanderschueren D, Demyttenaere K. Prevalence and predictors of sexual dysfunction in patients with type 1 diabetes. Diabetes Care 2003; 26: 409-414.
116. Enzlin P, et al. Sexual dysfunction in women with type 1 diabetes: a controlled study. Diabetes Care 2002; 25: 672-677.
117. Enzlin P, Mathieu C, Vanderschueren D, Demyttenaere K. Diabetes mellitus and female sexuality. a review of 25 years' research. Diabet Med 1998; 15: 809-815.
118. Saenz de Tejada I, Goldstein I, Azadzoi K, Krane RJ, Cohen RA. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 1989; 320: 1025-1030.
119. Azadzoi KM, Saenz de Tejada I. Diabetes mellitus impairs neurogenic and endothelium-dependent relaxation of rabbit corpus cavernosum smooth muscle. J Urol 1992; 148: 1587-1591.
120. Knispel HH, Goessl C, Beckmann R. Nitric oxide mediates relaxation in rabbit and human corpus cavernosum smooth muscle. Urol Res 1992; 20: 253-257.
121. Pickard RS, King P, Zar MA, Powell PH. Corpus cavernosal relaxation in impotent men. Br J Urol 1994; 74: 485-491.
122. Pickard RS, Powell PH, Zar MA. Nitric oxide and cyclic GMP formation following relaxant nerve stimulation in isolated human corpus cavernosum. Br J Urol 1995; 75: 516-522.
123. Keegan A, Cotter MA, Cameron NE. Effects of diabetes and treatment with the antioxidant alpha-lipoic acid on endothelial and neurogenic responses of corpus cavernosum in rats. Diabetologia 1999; 42: 343-350.
124. Giraldi A, et al. Effects of diabetes on neurotransmission in rat vaginal smooth muscle. Int J Impot Res 2001; 13: 58-66.
125. Vernet D, et al. Reduction of penile nitric oxide synthase in diabetic BB/WORdp (type I) and BBZ/WORdp (type II) rats with erectile dysfunction. Endocrinology 1995; 136: 5709-5717.
126. Cellek S, et al. Selective nitrergic neurodegeneration in diabetes mellitus - a nitric oxide-dependent phenomenon. Br J Pharmacol 1999; 128: 1804-1812.
127. El Sakka AI, Lin CS, Chui RM, Dahiya R, Lue TF. Effects of diabetes on nitric oxide synthase and growth factor genes and protein expression in an animal model. Int J Impot Res 1999; 11: 123-132.
128. Akingba AG, Burnett AL. Endothelial nitric oxide synthase protein expression, localization, and activity in the penis of the alloxan-induced diabetic rat. Mol Urol 2001; 5: 189-197.
129. Podlasek CA, et al. Characterization and localization of nitric oxide synthase isoforms in the BB/WOR diabetic rat. J Urol 2001; 166: 746-755.
130. Xu ZS, Fu Q, Zhao ST, Liu HN. Effect of diabetes and insulin treatment on nitric oxide synthase content in rat corpus cavernosum. Asian J Androl 2001; 3: 139-142.
131. Shotton HR, Clarke S, Lincoln J. The effectiveness of treatments of diabetic autonomic neuropathy is not the same in autonomic nerves supplying different organs. Diabetes 2003; 52: 157-164.
132. Escrig A, Marin R, Abreu P, Gonzalez-Mora JL, Mas M. Changes in mating behavior, erectile function, and nitric oxide levels in penile corpora cavernosa in streptozotocin-diabetic rats. Biol Reprod 2002; 66: 185-189.
133. Elabbady AA, Gagnon C, Hassouna MM, Begin LR, Elhilali MM. Diabetes mellitus increases nitric oxide synthase in penises but not in major pelvic ganglia of rats. Br J Urol 1995; 76: 196-202.
134. Cellek S, Foxwell NA, Moncada S. Two phases of nitrergic neuropathy in streptozotocin-induced diabetic rats. Diabetes 2003; 52: 2353-2362.
135. Abdelbaky TM, Brock GB, Huynh H. Improvement of erectile function in diabetic rats by insulin: possible role of the insulin-like growth factor system. Endocrinology 1998; 139: 3143-3147.
136. Jung GW, Kwak JY, Yoon S, Yoon JH, Lue TF. IGF-I and TGF-beta2 have a key role on regeneration of nitric oxide synthase (NOS)-containing nerves after cavernous neurotomy in rats. Int J Impot Res 1999; 11: 247-259.
137. Lumme A, Vanhatalo S, Soinila S. Axonal transport of nitric oxide synthase in autonomic nerves. J Auton Nerv Syst 1996; 56: 207-214.
138. Brownlee M. Glycosylation products as toxic mediators of diabetic complications. Annu Rev Med 1991; 42: 159-166.
139. Wolffenbuttel BH, Giordano D, Founds HW, Bucala R. Long-term assessment of glucose control by haemoglobin-AGE measurement. Lancet 1996; 347: 513-515.
140. Rodriguez-Manas L, et al. Early and intermediate Amadori glycosylation adducts, oxidative stress, and endothelial dysfunction in the streptozotocin-induced diabetic rats vasculature. Diabetologia 2003; 46: 556-566.
141. Cellek S, Qu W, Schmidt AM, Moncada S. Synergistic action of advanced glycation end products and endogenous nitric oxide leads to neuronal apoptosis in vitro: A new insight into selective nitrergic neuropathy in diabetes. Diabetologia 2004; 47: 331-339.
142. Seftel AD, et al. Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS. Urology 1997; 50: 1016-1026.
143. Ewing DJ. Diabetic autonomic neuropathy and the heart. Diabetes Res Clin Pract 1996; 30 Suppl: 31-36.
144. Clarke BE, Ewing DJ, Campbell IW. Diabetic autonomic neuropathy. Diabetologia 1979; 17: 195-212.
145. Engerman RL, Kern TS. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 1987; 36: 808-812.
146. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820.
147. Pieper GM, Dembny K, Siebeneich W. Long-term treatment in vivo with NOX-101, a scavenger of nitric oxide, prevents diabetes-induced endothelial dysfunction. Diabetologia 1998; 41: 1220-1226.
148. Sugimoto H, et al. Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy. Diabetologia 1998; 41: 1426-1434.
149. Biessels GJ, et al. Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment. Brain Res 1998; 800: 125-135.
150. Reagan LP, Mcewen BS. Diabetes, but not stress, reduces neuronal nitric oxide synthase expression in rat hippocampus: implications for hippocampal synaptic plasticity. Neuroreport 2002; 13: 1801-1804.
151. Stitt AW, Jenkins AJ, Cooper ME. Advanced glycation end products and diabetic complications. Expert Opin Investig Drugs 2002; 11: 1205-1223.
152. Kumari K, Murthy PS, Sahib MK. Monoaminoguanidine prevents sorbitol accumulation, nonenzymatic protein glycosylation and development of kidney lesions in diabetic rats. Experientia 1991; 47: 252-254.
153. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991; 40: 1328-1334.
154. Bannai C, et al. Amelioration of dermal lesions in streptozotocin-induced diabetic rats by aminoguanidine. Diabetes Res 1992; 20: 87-95.
155. Edelstein D, Brownlee M. Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. Diabetologia 1992; 35: 96-97.
156. Yagihashi S, Kamijo M, Baba M, Yagihashi N, Nagai K. Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes 1992; 41: 47-52.
157. Hammes HP, et al. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia 1994; 37: 32-35.
158. Soulis-Liparota T, Cooper ME, Dunlop M, Jerums G. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia 1995; 38: 387-394.
159. Sugimoto K, Yagihashi S. Effects of aminoguanidine on structural alterations of microvessels in peripheral nerve of streptozotocin diabetic rats. Microvasc Res 1997; 53: 105-112.
160. Cartledge JJ, Eardley I, Morrison JF. Advanced glycation end-products are responsible for the impairment of corpus cavernosal smooth muscle relaxation seen in diabetes. BJU Int 2001; 87: 402-407.
161. Stitt A, et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 2002; 51: 2826-2832.
162. Metz TO, Alderson NL, Thorpe SR, Baynes JW. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. Arch Biochem Biophys 2003; 419: 41-49.
163. Usta MF, et al. The Protective Effect of Aminoguanidine on Erectile Function in Streptozotocin Diabetic Rats. J Urol 2003; 170: 1437-1442.
164. Misko TP, et al. Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol 1993; 233: 119-125.
165. Vaitkevicius PV, et al. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc Natl Acad Sci USA 2001; 98: 1171-1175.
166. Kass DA, et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001; 104: 1464-1470.
167. Asif M, et al. An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci USA 2000; 97: 2809-2813.
168. Cooper ME, et al. The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation. Diabetologia 2000; 43: 660-664.
169. Candido R, et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 2003; 92: 785-792.
170. Wolffenbuttel BH, et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci USA 1998; 95: 4630-4634.
171. Forbes JM, et al. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 2003; 17: 1762-1764.
172. Khalifah RG, Baynes JW, Hudson BG. Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun 1999; 257: 251-258.
173. Cohen MP, et al. Inhibiting albumin glycation ameliorates diabetic nephropathy in the db/db mouse. Exp Nephrol 2000; 8: 135-143.
174. Degenhardt TP, et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002; 61: 939-950.
175. Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine. J Biol Chem 2000; 275: 21177-21184.
176. Price DL, Rhett PM, Thorpe SR, Baynes JW. Chelating activity of advanced glycation end-product inhibitors. J Biol Chem 2001; 276: 48967-48972.
177. Voziyan PA, et al. Modification of proteins In vitro by physiological levels of glucose: Pyridoxamine inhibits conversion of amadori intermediate to advanced glycation end-products through binding of redox metal ions. J Biol Chem 2003;
178. Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J Clin Invest 1994; 94: 110-117.
179. Schmidt AM, Stern DM. RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrinol Metab 2000; 11: 368-375.
180. Schmidt AM, et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 1992; 267: 14987-14997.
181. Hudson BI, et al. Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders. Arch Biochem Biophys 2003; 419: 80-88.
182. Schmidt AM, et al. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci USA 1994; 91: 8807-8811.
183. Tsuji H, et al. Ribozyme targeting of receptor for advanced glycation end products in mouse mesangial cells. Biochem Biophys Res Commun 1998; 245: 583-588.
184. Wautier JL, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 1996; 97: 238-243.
185. Park L, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998; 4: 1025-1031.
186. Lalla E, et al. Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Clin Invest 2000; 105: 1117-1124.
187. Yorek MA. The role of oxidative stress in diabetic vascular and neural disease. Free Radic Res 2003; 37: 471-480.
188. Wautier MP, et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001; 280: E685-E694.
189. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47: 859-866.
190. Rajagopalan S, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916-1923.
191. Cotter MA, Cameron NE. Effect of the NAD(P)H oxidase inhibitor, apocynin, on peripheral nerve perfusion and function in diabetic rats. Life Sci 2003; 73: 1813-1824.
192. Cameron NE, Cotter MA, Jack AM, Basso MD, Hohman TC. Protein kinase C effects on nerve function, perfusion, Na(+), K(+)-ATPase activity and glutathione content in diabetic rats. Diabetologia 1999; 42: 1120-1130.
193. Cotter MA, Jack AM, Cameron NE. Effects of the protein kinase C beta inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes. Clin Sci (Lond) 2002; 103: 311-321.
194. Frank RN. Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. Am J Ophthalmol 2002; 133: 693-698.
195. Cameron NE, Cotter MA, Robertson S. Angiotensin converting enzyme inhibition prevents development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocin-diabetic rats. Diabetologia 1992; 35: 12-18.
196. Malik RA, et al. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998; 352: 1978-1981.
197. Aggarwal M, Singh J, Sood S, Arora B. Effects of lisinopril on streptozotocin-induced diabetic neuropathy in rats. Methods Find Exp Clin Pharmacol 2001; 23: 131-134.
198. Maxfield EK, Love A, Cotter MA, Cameron NE. Nerve function and regeneration in diabetic rats: effects of ZD-7155, an AT1 receptor antagonist. Am J Physiol 1995; 269: E530-E537.
199. Cameron NE, Cotter MA, Maxfield EK, Anti-oxidant treatment prevents the development of peripheral nerve dysfunction in streptozotocin-diabetic rats. Diabetologia 1993; 36: 299-304.
200. van Dam PS, Bravenboer B, van Asbeck BS, Marx JJ, Gispen WH. High rat food vitamin E content improves nerve function in streptozotocin-diabetic rats. Eur J Pharmacol 1999; 376: 217-222.
201. Cameron NE, Cotter MA. Effects of antioxidants on nerve and vascular dysfunction in experimental diabetes. Diabetes Res Clin Pract 1999; 45: 137-146.
202. Keegan A, Cotter MA, Cameron NE. Corpus cavernosum dysfunction in diabetic rats: effects of combined alpha-lipoic acid and gamma-linolenic acid treatment. Diabetes Metab Res Rev 2001; 17: 380-386.
203. Manzella D, Barbieri M, Ragno E, Paolisso G. Chronic administration of pharmacologic doses of vitamin E improves the cardiac autonomic nervous system in patients with type 2 diabetes. Am J Clin Nutr 2001; 73: 1052-1057.
204. Bursell SE, et al. High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. Diabetes Care 1999; 22: 1245-1251.
205. Murdoch A. Human embryonic stem cells: an introduction. Hum Fertil (Camb) 2002; 5: 203-205.
206. Preston SL, et al. The new stem cell biology: something for everyone. Mol Pathol 2003; 56: 86-96.
207. Asahara T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-967.
208. Kocher AA, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001; 7: 430-436.
209. Strauer BE, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002; 106: 1913-1918.
210. Krause DS, et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell 2001; 105: 369-377.
211. Brittan M, et al. Bone marrow derivation of pericryptal myofibroblasts in the mouse and human small intestine and colon. Gut 2002; 50: 752-757.
212. Direkze NC, et al. Multiple organ engraftment by bone-marrow-derived myofibroblasts and fibroblasts in bone-marrow-transplanted mice. Stem Cells 2003; 21: 514-520.
213. Levinsson A, et al. Functional connections are established in the deafferented rat spinal cord by peripherally transplanted human embryonic sensory neurons. Eur J Neurosci 2000; 12: 3589-3595.
214. Mitsui T, et al. Immortalized neural stem cells transplanted into the injured spinal cord promote recovery of voiding function in the rat. J Urol 2003; 170: 1421-1425.
215. Soria B, et al. Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice. Diabetes 2000; 49: 157-162.
216. Lumelsky N, et al. Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. Science 2001; 292: 1389-1394.
217. Ianus A, Holz GG, Theise ND, Hussain MA. In vivo derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion. J Clin Invest 2003; 111: 843-850.
218. Liechty KW, et al. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med 2000; 6: 1282-1286.
219. Gussoni E, et al. Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature 1999; 401: 390-394.
220. Horwitz EM, et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 2001; 97: 1227-1231.
221. Stepanovic V, Awad O, Jiao C, Dunnwald M, Schatteman GC. Leprdb diabetic mouse bone marrow cells inhibit skin wound vascularization but promote wound healing. Circ Res 2003; 92: 1247-1253.
222. Schatteman GC, Hanlon HD, Jiao C, Dodds SG, Christy BA. Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. J Clin Invest 2000; 106: 571-578.
223. Salonia A, Rigatti P, Montorsi F. Sildenafil in erectile dysfunction: a critical review. Curr Med Res Opin 2003; 19: 241-262.
224. Qiu Y, Kraft P, Craig EC, Liu X, Haynes-Johnson D. Identification and functional study of phosphodiesterases in rat urinary bladder. Urol Res 2001; 29: 388-392.
225. Qiu Y, Kraft P, Craig EC, Liu X, Haynes-Johnson D. Cyclic nucleotide phosphodiesterases in rabbit detrusor smooth muscle. Urology 2002; 59: 145-149.
226. Cashen DE, MacIntyre DE, Martin WJ. Effects of sildenafil on erectile activity in mice lacking neuronal or endothelial nitric oxide synthase. Br J Pharmacol 2002; 136: 693-700.
227. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999; 281: 421-426.
228. Perimenis P, et al. Switching from long-term treatment with self-injections to oral sildenafil in diabetic patients with severe erectile dysfunction. Eur Urol 2002; 41: 387-391.
229. Cellek S, Rees RW, Kalsi J. A Rho-kinase inhibitor, soluble guanylate cyclase activator and nitric oxide-releasing PDE5 inhibitor: novel approaches to erectile dysfunction. Expert Opin Investig Drugs 2002; 11: 1563-1573.
230. Rees RW, Ralph DJ, Royle M, Moncada S, Cellek S. Y-27632, an inhibitor of Rho-kinase, antagonizes noradrenergic contractions in the rabbit and human penile corpus cavernosum. Br J Pharmacol 2001; 133: 455-458.
231. Rees RW, et al. Human and rabbit cavernosal smooth muscle cells express Rho-kinase. Int J Impot Res 2002; 14: 1-7.
232. Chitaley K, et al. Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat Med 2001; 7: 119-122.
233. Chitaley K, et al. Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat Med 2001; 7: 119-122.
234. Buyukafsar K, Un I. Effects of the Rho-kinase inhibitors, Y-27632 and fasudil, on the corpus cavernosum from diabetic mice. Eur J Pharmacol 2003; 472: 235-238.
235. Nakane M, et al. Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: synergism of nitric oxide and YC-1. Int J Impot Res 2002; 14: 121-127.
236. Mizusawa H, Hedlund P, Brioni JD, Sullivan JP, Andersson KE. Nitric oxide independent activation of guanylate cyclase by YC-1 causes erectile responses in the rat. J Urol 2002; 167: 2276-2281.
237. Hsieh GC, O'Neill AB, Moreland RB, Sullivan JP, Brioni JD. YC-1 potentiates the nitric oxide/cyclic GMP pathway in corpus cavernosum and facilitates penile erection in rats. Eur J Pharmacol 2003; 458: 183-189.
238. Kalsi JS, et al. BAY41-2272, a novel nitric oxide independent soluble guanylate cyclase activator, relaxes human and rabbit corpus cavernosum in vitro. J Urol 2003; 169: 761-766.
239. Bischoff E, Schramm M, Straub A, Feurer A, Stasch JP. BAY 41-2272: a stimulator of soluble guanylyl cyclase induces nitric oxide-dependent penile erection in vivo. Urology 2003; 61: 464-467.
240. Kalsi JS, Ralph DJ, Madge DJ, Kell PD, Cellek S. A comparative study of sildenafil, NCX-911 and BAY41-2272 on the anococcygeus muscle of diabetic rats. Int J Impot Res 2004 Mar 18 [Epub ahead of print].
241. Riffaud JP, Bernabe J, Giuliano F, Jones R, Jeremy JY. Pharmacological profile of sildenafil nitrate (NCX-911) in various models of erectile dysfunction. Inflammation Res 2001; 50: S84.
242. Seidler M, et al. In vitro effects of a novel class of nitric oxide (NO) donating compounds on isolated human erectile tissue. Eur Urol 2002; 42: 523-528.
243. Kalsi JS, Kell PD, Cellek S, Ralph DJ. NCX-911, a novel nitric oxide-releasing PDE5 inhibitor relaxes rabbit corpus cavernosum in the absence of endogenous nitric oxide. Int J Impot Res 2004; 16: 195-200.
244. Domenico R. Pharmacology of nitric oxide: molecular mechanisms and therapeutic strategies. Curr Pharm Design 2004; 10(14): 1667-76.
245. Napoli C, Sica V. Statin treatment and the natural history of atherosclerotic-related diseases: pathogenic mechanisms and the risk-benefit profile. Curr Pharm Design 2004; 10(4): 425-32.
246. Tiboni GM, Clementini E. Teratological consequences of nitric oxide synthesis inhibition. Curr Pharm Design 2004; 10(22): 2759-67.